| Project/Area Number |
18K09067
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56020:Orthopedics-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | Precision medicine / 骨軟部腫瘍 / 末梢血免疫関連マーカー / エリブリン / 分子標的治療 / 薬剤耐性 / 軟部肉腫 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
The resistance of malignant bone and soft tissue tumors, especially soft tissue sarcomas, to anti-tumor drugs is a major problem. In this project, we studied the biological characteristics of malignant bone and soft tissue tumors, and obtained research results on the basis of Precision Medicine, especially from the viewpoint of drug resistance, focusing on the following three points. (1) The efficacy of eribulin (Eri), a typical treatment for soft tissue sarcoma, can be predicted using peripheral blood immune-related markers. (2) Expression of Beta-tublin3 is a biomarker of drug resistance in Eri. (3) In giant cell tumor of bone, it is possible to predict osteosclerosis after anti-RANKL antibody administration by evaluating the nuclear translation of beta-catenin.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、軟部腫瘍を中心とした悪性骨軟部腫瘍の生物学的特性に関する研究が進んだ。上述の成果により、使用可能な限られたリソース(薬剤)を適切に選択する根拠が明らかとなった。即ち、薬剤投与前に適切に検査を行うことにより、薬剤の治療効果、ひいては各々の症例の予後を改善させることが可能になると思われた。
|
